CLSA Raises Target Price for GENFLEET-B to HK$61.9, Keeps Outperform Rating

Stock News03-26 11:17

CLSA released a research report indicating that GENFLEET-B (02595) reported revenue of RMB 130 million last year, a year-on-year increase of 24.42%. R&D expenses were RMB 282 million, down 15.01% year-on-year. The net loss widened by 164.82% to RMB 1.795 billion, with all figures surpassing market expectations. The G12D candidate GFH375 has entered the registration trial phase for pancreatic cancer, while pan-RAS candidate GFH276 is expected to become a long-term growth driver for GENFLEET. Positive safety signals have already been observed in the Phase I dose-escalation trial for GFH276. The firm raised its profit forecasts for the company for this year and next by 4% and 5.3%, respectively. It increased the target price from HK$60.8 to HK$61.9 and maintained an Outperform rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment